Affimed Total Liabilities 2014-2024 | AFMDQ
Affimed total liabilities from 2014 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Affimed Annual Total Liabilities
(Millions of US $) |
| 2023 |
$43 |
| 2022 |
$50 |
| 2021 |
$106 |
| 2020 |
$118 |
| 2019 |
$83 |
| 2018 |
$90 |
| 2017 |
$13 |
| 2016 |
$11 |
| 2015 |
$13 |
| 2014 |
$13 |
| 2013 |
$0 |
| 2012 |
$0 |
Affimed Quarterly Total Liabilities
(Millions of US $) |
| 2024-09-30 |
$25 |
| 2024-06-30 |
$26 |
| 2024-03-31 |
$32 |
| 2023-12-31 |
$43 |
| 2023-09-30 |
$48 |
| 2023-06-30 |
$39 |
| 2023-03-31 |
$46 |
| 2022-12-31 |
$50 |
| 2022-09-30 |
$56 |
| 2022-06-30 |
$72 |
| 2022-03-31 |
$85 |
| 2021-12-31 |
$106 |
| 2021-09-30 |
$102 |
| 2021-06-30 |
$117 |
| 2021-03-31 |
$123 |
| 2020-12-31 |
$118 |
| 2020-09-30 |
$71 |
| 2020-06-30 |
$67 |
| 2020-03-31 |
$73 |
| 2019-12-31 |
$83 |
| 2019-09-30 |
$70 |
| 2019-06-30 |
$74 |
| 2019-03-31 |
$77 |
| 2018-12-31 |
$90 |
| 2018-09-30 |
$15 |
| 2018-06-30 |
$15 |
| 2018-03-31 |
$15 |
| 2017-12-31 |
$13 |
| 2017-09-30 |
$14 |
| 2017-06-30 |
$14 |
| 2017-03-31 |
$10 |
| 2016-12-31 |
$11 |
| 2016-09-30 |
$11 |
| 2016-06-30 |
$10 |
| 2016-03-31 |
$13 |
| 2015-12-31 |
$13 |
| 2015-09-30 |
$10 |
| 2015-06-30 |
$10 |
| 2015-03-31 |
$10 |
| 2014-12-31 |
$13 |
| 2014-09-30 |
$13 |
| 2014-06-30 |
|
| 2014-03-31 |
|
| 2013-09-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.009B |
|
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
|
